Bausch + Lomb (BLCO) to Release Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect Bausch + Lomb to post earnings of $0.16 per share for the quarter. Bausch + Lomb has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.13 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.13. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Bausch + Lomb had a positive return on equity of 3.36% and a negative net margin of 10.15%. The business’s revenue was up 17.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.18 earnings per share. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Stock Up 1.4 %

Shares of NYSE:BLCO opened at $20.46 on Monday. The company’s fifty day moving average is $18.17 and its 200-day moving average is $16.27. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.01 and a current ratio of 1.65. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69. The company has a market capitalization of $7.20 billion, a PE ratio of -21.31, a P/E/G ratio of 1.76 and a beta of 0.48.

Insider Buying and Selling at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders purchased 32,250 shares of the stock in a transaction dated Monday, August 5th. The stock was bought at an average price of $15.66 per share, for a total transaction of $505,035.00. Following the transaction, the chief executive officer now directly owns 595,169 shares in the company, valued at $9,320,346.54. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.15% of the company’s stock.

Wall Street Analyst Weigh In

BLCO has been the topic of a number of recent analyst reports. Raymond James began coverage on shares of Bausch + Lomb in a research report on Wednesday, July 10th. They issued an “outperform” rating and a $19.00 price target on the stock. Evercore ISI upgraded Bausch + Lomb from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $19.00 to $25.00 in a research report on Tuesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research report on Monday, September 16th. Royal Bank of Canada increased their target price on Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, October 22nd. Finally, Stifel Nicolaus raised their target price on Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research note on Monday, September 23rd. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Bausch + Lomb has a consensus rating of “Moderate Buy” and a consensus target price of $20.27.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.